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Abstract
Hypertension is a prevalent condition worldwide and is the key risk factor for fatal cardiovascular complications, such
as stroke, sudden cardiac death and heart failure. Reduced bioavailability of nitric oxide (NO) in the endothelium is an
important precursor for impaired vasodilation and hypertension. In the heart, NO deficiency deteriorates the adverse
consequences of pressure-overload and causes cardiac hypertrophy, fibrosis and myocardial infarction which lead to
fatal heart failure and sudden cardiac death. Recent consensus is that both endothelial and neuronal nitric oxide
synthases (eNOS or NOS3 and nNOS or NOS1) are the constitutive sources of NO in the myocardium. Between the
two, nNOS is the predominant isoform of NOS that controls intracellular Ca2+ homeostasis, myocyte contraction,
relaxation and signaling pathways including nitroso-redox balance. Notably, our recent research indicates that cardiac
eNOS protein is reduced but nNOS protein expression and activity are increased in hypertension. Furthermore, nNOS is
induced by the interplay between angiotensin II (Ang II) type 1 receptor (AT1R) and Ang II type 2 receptor (AT2R),
mediated by NADPH oxidase and reactive oxygen species (ROS)-dependent eNOS activity in cardiac myocytes. nNOS,
in turn, protects the heart from pathogenesis via positive lusitropy in hypertension. Soluble guanylate cyclase (sGC)-
cGMP/PKG-dependent phosphorylation of myofilament proteins are novel targets of nNOS in hypertensive
myocardium. In this short review, we will endeavor to overview new findings of the up-stream and downstream
regulation of cardiac nNOS in hypertension, shed light on the underlying mechanisms which may be of therapeutic
value in hypertensive cardiomyopathy.
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Background
According to World Health Organization, over 1 billion
people are associated with hypertension worldwide and
the number of subjects with such disorder rises signifi-
cantly in aged group [1–4]. Importantly, population with
hypertension is in an upsurge in young generation.
Attention should be drawn to this trend because the
prevalent exposure to the risk factors for hypertension
during early stage of the lifespan is likely to expend to
the trajectory of later life of their adulthood [5] (“pro-
gramming” for hypertension). Furthermore, hypertension-
associated complication in the cardiovascular system is
one of the most important causes of premature death
worldwide (up to 45 % of death due to heart diseases). As
such, the global economic burden of healthcare expend-
iture due to hypertension maintains a steady increase. So
far, effective regime for hypertension or hypertension-
related therapy for heart diseases is lacking.
Sustained pressure-overload in conjunction with sys-
tematic inflammation, oxidative stress and endothelial
dysfunction in hypertension stimulates a series of ad-
verse outcomes of the heart, including ventricular hyper-
trophy [6], collagen deposition or fibrosis [7], dilatation
[8] and coronary artery stiffening or rarefaction [9, 10].
The fundamental mechanisms those cause these changes
involve altered ion channels and transporters in the
plasmalemmal membrane of cardiac myocytes; abnormal
calcium handling in cardiac myocytes; metabolic derange-
ment; sarcomere disorganization and changes in the wide
spectrum of intracellular signaling pathways [6, 11–17].
Concomitant to the progression of hypertension-induced
adverse remodeling of myocardium, a number of en-
dogenous defense mechanisms can be triggered, which are
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involved in delaying and preventing the pathological pro-
cesses. These defense mechanisms include: maintaining or
stimulating cGMP pathway, e.g. nitric oxide [18], atrial
natriuretic peptide [19, 20] and phosphodiesterase 5 inhib-
ition [21]; antagonizing beta1-adrenergic pathway [22], e.g.
beta3-adrenoreceptor- or muscarinic receptor dependent
signaling pathways; AT2R, Ang 1–7 or 1–9 receptors and
Mas receptor that antagonizes AT1R signaling [23–25]; me-
tabolisms and AMPK signaling [26]. General consensus is
that nNOS is an important cardiac protector in healthy and
diseased hearts. In this review, we will highlight our novel
findings in nNOS and its protective mechanisms of the
heart in hypertension.
NO, eNOS and nNOS in the hypertensive myocardium
NO is an important autocrine and paracrine signaling
molecule that plays crucial roles in regulating cardiovas-
cular physiology and pathology. Deficiency in NO are as-
sociated with oxidative stress, diastolic dysfunction and
most of adverse cardiovascular disorders including heart
failure and cardiac arrhythmias [18]. Two constitutive
NO synthases (cNOS) are responsible for the production
of NO in healthy myocardium: eNOS and nNOS, which
share similar structure and mechanism of activation.
In general, the active NOSs form a homodimer and
convert the amino acid L-arginine to L-citrulline and
NO (Fig. 1). NOS monomer contains a C-terminal
reductase domain and a N-terminal oxygenase domain
which are linked by calmodulin (CaM) binding region.
The N-terminal oxidase domain contains the heme,
tetrahydrobiopterin cofactors (BH4) and the binding site
for the substrate arginine. Oxidase domain is the active
site of NO synthesis. The reductase domain is composed
of the flavin mononucleotide (FMN)-binding subdomain,
the flavin adenine dinucleotide (FAD) and reduced
nicotinamide-adenine dinucleotide phosphate (NADPH)-
binding subdomains. During catalysis, the electrons are
transferred from NADPH to FAD and FMN of one mono-
mer to the heme domain of the opposite monomer [27].
Production of NO requires oxygen as the electron
acceptor. NO diffuses freely across the plasma membrane,
therefore, NO is generally known to be able to transport
to the effector proteins in the cells or in the adjacent cells
and exerts its effects (e.g. endothelial NO targets soluble
guanylate cyclase, sGC, in smooth muscle to accomplish
vasodilation).
In fact, NO is highly reactive with short life-time
(a few seconds). Therefore, the likelihood of NO to
travel a distance to reach the target proteins in myo-
cardium is low (especially given the oxidative environment
of myocardium); instead, NO is produced from eNOS and
nNOS in the designated compartments and affect down-
stream targets in confined location where the enzymes
reside [27, 28]. The spatial regulation enhances the effect-
iveness of NO and the producing enzymes to fulfill
specific tasks.
It should be noted that eNOS and nNOS are localized
at discrete compartments and exert diverse functions in
cardiomyocytes. E.g. eNOS is localized in the caveolae of
cardiomyocytes and nNOS is in the cytosol with
Fig. 1 Structure of an active nNOS protein. Schematic diagram shows the two monomers of nNOS (each contains an oxygenase domain (−COOH terminal)
and a reductase domain (−NH2 terminal). Electrons transfer from NADPH in the reductase domain of one monomar (via FDA and FMN) to the heme iron in
the oxygenase domain of the other monomer, facilitated by calmodulin (CaM), enable nNOS to catalyze the oxidation of L-arginine to L-citrulline and releases
NO. Ca2+ activates CaM and nNOS activity
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ryanodine receptors (RyR) in the sarcoplasmic reticulum
(SR) in healthy heart. The clear distinction in
compartmentalization between eNOS and nNOS are dis-
arranged in diseased hearts. E.g. eNOS expression is
often found to be diminished and nNOS translocates
from SR to plasmalemmal membrane [29–31]. The
changes in the location of nNOS enable it to affect
different downstream targets for different functions.
The pathological stimuli may also change the property
of eNOS or nNOS in the hypertension. eNOS has been
found to be uncoupled in the myocardium of a mice
model of transverse aortic constriction (TAC)-induced
pressure overload and eNOS produces superoxide rather
than NO [32–34]. Increased oxidative stress and deple-
tion of BH4 due to the oxidation of BH4 to BH2 is one
of the dominant mechanisms for eNOS uncoupling, con-
sequently, eNOS becomes responsible for cardiac oxida-
tive stress, left ventricular (LV) hypertrophy and
dysfunction [32–34]. In its “coupled” state, eNOS-
derived NO can be an important protective mechanism
for TAC-induced LV hypertrophy [35–38]. In addition,
eNOS is known to be an “endogenous beta-blocker” by
restoring the sympatho-vagal balance, promoting vaso-
dilatation and neoangiogenesis [39] and protects the
heart under pathological stress.
In contrast, nNOS has consistently been shown to be
upregulated in LV myocardium from the hearts of
pressure-overload [40, 41]. Similarly, the activity of
nNOS (phosphorylated:total nNOS ratio) is significantly
increased in right ventricular (RV) myocardium of
pulmonary hypertensive rats [42], confirming the upreg-
ulation of myocardial nNOS with increased pressure-
overload. Accumulating evidence shows that nNOS
up-regulation in diseased heart is cardiac protective:
nNOS has been shown to inhibit xanthine oxidoreduc-
tase [43, 44] or NADPH oxidases [45, 46] and mitochon-
dria production of ROS [47], as a result, reduces
oxidative stress and suppresses adverse myocardial
remodeling. In addition, nNOS facilitates the relaxation
of LV myocytes and maintains lusitropy of the heart
under pressure-overload. Since increased oxidative stress
and diastolic dysfunction are often associated with struc-
tural and functional pathology of the myocardium, such
as hypertrophy, arrhythmias and heart failure, nNOS
modulation of various cardiac oxidases or improving
diastolic function of the myocardium under pressure-
overload enable nNOS to protect the heart from struc-
tural and functional remodeling those underlie fatal
heart failure.
nNOS protein expression and activity in hypertensive
myocardium
The mechanisms leading to nNOS up-regulation in
diseased heart remain unclear. One of the suggestions is
that the transcription and the translation of nNOS are
oxygen-dependent. Hypoxia (8 %, 48 h) has convincingly
show to increase the mRNA and protein expressions as
well as the activity of nNOS in the systematic and local
arteries (aorta, mesenteric arterioles and renal papilla)
and in the brain by revealing a novel promotor region in
exon 2 with increased translational efficiency [48].
Whether limited availability of O2 in hypertensive myo-
cardium is essential in triggering nNOS up-regulation
has not been elucidated yet.
Intriguingly, our recent results demonstrated that Ang
II induces nNOS under the conditions where ROS are
increased (Fig. 2). In isolated LV myocytes, Ang II treat-
ment (3 h) significantly increased nNOS protein expres-
sion and activity via AT1R stimulation of NADPH
oxidase activity and ROS production [45, 49]. In
addition, nNOS in LV myocytes is increased in Ang
II-induced hypertensive rats [50] (Fig. 2). In both cases,
Ang II only stimulated nNOS but not eNOS because
eNOS protein expression is either not changed (with
acute Ang II treatment) or significantly reduced (in
hypertension) [45, 50]. This is in contrast to the findings
shown previously where Ang II treatment in vivo in-
creased eNOS protein expression in the myocardium
[51, 52]. Therefore, Ang II or AT1R has been impli-
cated in the activation of constitutive NOS in cardio-
vascular system.
Mechanistic studies showed that NADPH oxidase is
essential in mediating AT1R-dependent and ROS-
stimulated signaling (Fig. 2). NADPH oxidase/ROS acti-
vates eNOS-phosphorylation and mediates eNOS-derived
NO-dependent S-nitrosation of AT2R. Site specific muta-
genesis analysis indicated that among 4 intracellular cyst-
eine residues in AT2R, cysteine349 of AT2R is the key
regulatory site for AT2R translocation to the plasma
membrane [49]. Our results are in line with other reports
showing the relationship between AT2R and nNOS. E.g.
C21, an AT2R agonist, significantly increased nNOS
expression in the paraventricular hypothalamic nucleus
(PVN) and rostral ventrolateral medulla (RVLM) [53, 54]
or inhibition of AT2R abolishes relaxin-induced nNOS
protein expression and phosphorylation [55]. Furthermore,
nNOS is unaffected in the infarcted myocardium from
AT2R gene deficient mice [56], confirming the role of
AT2R in nNOS up-regulation. In hypertensive myocar-
dium, protein expressions of AT1R and AT2R are not
changed comparing to those in sham rats (unpublished
data). It is possible to extrapolate that ROS may function as
an important trigger signal to nNOS up-regulation at least
at early stage of myocardial stress. Subsequent eNOS/NO-
dependent S-nitrosation of AT2R and its downstream
signaling cascades are pivotal in the transcription and trans-
lation of nNOS proteins. Our results are the first to reveal
the interplay between AT1R and AT2R or eNOS and AT2R
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in regulating nNOS protein expression in cardiac myocytes.
Application of the knowledge to the therapeutic strategy to-
wards hypertension and pressure-overload-induced adverse
remodeling will be beneficial.
S-nitrosylation vs. soluble guanylate cyclase – cGMP
pathway of nNOS in hypertensive myocardium
It is generally considered that the primary signaling pathway
of NO is through the activation of soluble guanylyl cyclase
(sGC) leading to the production of cyclic guanosine mono-
phosphate (cGMP) and protein kinase G (PKG)-dependent
phosphorylation of downstream proteins. However, it
should be noted that the prototypic mechanism of NO in-
volves direct modifications of a diverse range of proteins by
S-nitrosylation (or S-nitrosation) of cysteine residues [57]. It
turns out that the reaction between NO and target proteins
are highly specific, requires substantially low concentration
of NO and the process is actively regulated. The high speci-
ficity of NO-protein modification is achieved by NOSs being
part of the signaling mechanism in protein complexes, in
which S-nitrosylation or S-nitrosothiol (SNO) interaction
occurs at the sites within the vicinity of NOSs.
NO activation of sGC/cGMP for PKG-dependent sig-
naling requires high concentrations of NO [58]. I.e. NO
activates sGC moderately via a classical heme-dependent
mechanism at low NO concentration. However, at high
concentration of NO, the activity of sGC can be increased
by the order of 2 via heme-independent but via direct
NO-cysteine interaction of sGC. Therefore, the concentra-
tion of NO near the vicinity of target proteins determine
whether sGC is activated and cGMP/PKG-dependent
pathway mediates the responses of NOSs.
It is well established that under normal conditions and in
healthy heart, endothelial NO induces the relaxation via
Fig. 2 Schematic diagram of nNOS up-regulation by Ang II in cardiac myocytes and the potential target proteins, mechanism of regulation in cardiac
myocytes from hypertension. Left. Ang II stimulates AT1R and NADPH oxidase in cardiac myocytes. AT1R and intracellular ROS activates Akt and
phosphorylates endogeneous eNOS to produce NO. eNOS and NO-dependent S-nitrosation of AT2R lead to the translocation of AT2R to the plasma
membrane and induces nNOS protein and increases NO production (data modified from Figure 8 of Basic Research in Cardiology, 2015, 110 (3):21). In
hypertension, cardiac nNOS is up-regulated and facilitates myocyte relaxation. nNOS reduces Ca2+ influx via LTCC and promotes Ca2+ re-uptake via
SERCA through PLN phosphorylation (secondary to PPase-dependent PKA phosphorylation) in healthy heart. In hypertension, nNOS inhibits LTCC and
phosphorylates cMBP-C Ser273 and cTnI Ser23/24 via cGMP/PKG-dependent mechanism. As a result, myofilament Ca2+ sensitivity is reduced which
accounts for nNOS-dependent positive lusitropy in hypertension
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cGMP/PKG-dependent phosphorylation of myosin phos-
phatases in smooth muscle. In cardiac myocytes, however,
the effect of nNOS on myocyte relaxation is independent of
cGMP/PKG-dependent signaling, rather it is mediated by
stimulating Ca2+ reuptake through Ca2+ ATPase in the SR
(SERCA) via PKA-dependent phosphorylation of phospho-
lamban at Ser [16] (PLN-p) [59]. The increased PKA-
dependent phosphorylation is through nNOS-dependent
inhibition of protein phosphatase 2A (PP2A) activity [59].
Interestingly, in LV myocytes treated with Ang II or
from hypertensive hearts, increased nNOS activity facili-
tated myocyte relaxation via cGMP/PKG-dependent
phosphorylations of PLN or cGMP/PKG-dependent
phosphorylations of myosin binding protein C (cMyBPC-
Ser273) and troponin I (cTnI-Ser23/24) (Fig. 2). As a result,
nNOS reduces myofilament Ca2+ sensitivity and promotes
myocyte relaxation in hypertension [50]. Inhibition of
PKA-dependent signaling failed to prevent the effect of
nNOS under these conditions. These results suggest that
the downstream mediating mechanisms of nNOS-derived
NO are shifted from sGC/cGMP-independent and PKA-
dependent signaling pathway in healthy heart to cGMP/
PKG-dependent mechanism in hypertensive hearts, pre-
sumably due to the greater bioavailability of NO from
nNOS (Fig. 2). Similarly, cGMP/PKG-dependent signaling
has been suggested to mediate the functions of nNOS
following conditional nNOS over-expression in the myocar-
dium in mice or lentiviral over-expression of nNOS in rats
[60, 61]. Conversely, reducing myocardial nNOS and its ac-
tivity in PMCA4b transgenic mice [62] or in the dystrophin
deficiency model [63] decreased myocyte cGMP levels.
Recently, Kass’s group have shown that there are two
pools of sGC in cardiac myocytes (caveolin-enriched
membrane and nonlipid raft) with the former pool produ-
cing 2–3 fold more cGMP following NO stimulation [64].
Since nNOS up-regulation is known to be associated with
translocation from SR to caveolae in the heart under stress
[29–31] it is possible to postulate that nNOS up-
regulation in diseased hearts or in response to pathogenic
stimuli, e.g. Ang II, is associated with its translocation to
the location where sGC is reachable with enhanced
efficiency to produce greater amount of cGMP.
Therefore, the primary mechanism that mediates the
effect of nNOS is S-nitrosylation or S-nitrosation of the
cysteine residues of target proteins. Subsequently, the
genre of downstream target proteins of NO determines
the form of regulation in the signaling cascade. E.g.
under the conditions of increased nNOS protein
expression and activity, NO stimulates sGC (through
S-nitrosation) and initiates cGMP/PKG-dependent sig-
naling pathway. Alternatively, regulation of cardiac
oxidases is able to affect downstream target proteins
(e.g. Ca2+ handling proteins) to propagate the redox
and Ca2+ signals, respectively.
Proteins targeted by nNOS in healthy and hypertensive heart
So far, the downstream target proteins of nNOS and its
mode of regulation in healthy and diseased myocardium
are not fully understood. Key excitation-contraction
coupling proteins are known to be targeted by nNOS:
L-type Ca2+ channels [65, 66], RyR [31], PLN [59],
voltage-gated sodium channels (Nav1.5) [67] as well as
structure proteins, such as syntrophin [67]. Recently, we
have reported that myofilament proteins (cMyBPC and
cTnI) are targeted by nNOS and nNOS-dependent alter-
ations in the phosphorylation and change the myofila-
ment Ca2+ sensitivity [50]. Although nNOS-dependent
regulation of myofilament proteins is not clear at
present, our preliminary results suggest that the myo-
filament proteins those are regulated by nNOS are
different between sham and hypertension, implicating
the significance of nNOS in regulating cardiac myofil-
ament (Fig. 2).
The detailed signaling molecules those are targeted by
nNOS and the differences in healthy and diseased hearts
remain undetermined. Cardiac oxidases (including
xanthine oxidoreductase, NADPH oxidase or mitochon-
drial cytochrome C oxidases or eNOS) are probably the
key targets of nNOS in the heart under pressure-
overload and regulation of which induces a plethora of
responses involving oxidation, reduction, phosphoryl-
ation and various types of post-transcriptional regula-
tions [68]. Other proteins such as sGC or PPs, whose
activity are important in the hearts, are likely to play
important roles mediating the effects of nNOS in hyper-
tensive heart.
Conclusion
Hypertension is a common condition that leads to fatal
cardiovascular complications such as myocardial infarc-
tion, stroke, sudden cardiac death and heart failure.
Myocardial hypertrophy by sustained pressure-overload
is the adverse remodeling in hypertension that predis-
poses to the apoptosis and fibrosis, malignant conse-
quences upon pathogenic stimuli. During the pathological
progression in the myocardium, nNOS is up-regulated
and NO-derived pathway is associated with the prevention
of cardiac hypertrophy by targeting oxidative stress, hyper-
trophic pathways and abnormal Ca2+ handlings. Our
recent research reveals some of the important mecha-
nisms of the upstream and downstream regulation of
nNOS in hypertensive myocardium. Our results highlight
that AT1R, NADPH oxidase/ROS and AT2R are import-
ant up-stream regulators of the transcription of nNOS in
the myocardium under pressure-overload. In addition,
nNOS-derived NO leads to cGMP/PKG-dependent phos-
phorylation of downstream target proteins including those
in the SR and in the myofilament. Results from our
research suggest that nNOS regulation of myofilament
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proteins is important in facilitating relaxation of the heart
in hypertension. Our results reveal novel targets those
possesses important clinical value in preventing the
adverse remodeling with pressure-overload in the heart.
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